Immunovant, Inc. (NASDAQ:IMVT) Receives Consensus Rating of “Moderate Buy” from Brokerages
Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has earned an average recommendation of “Moderate Buy” from the ten analysts that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the […]
Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has earned an average recommendation of “Moderate Buy” from the ten analysts that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the […]
